Convalescent Plasma for COVID-19 Research (CONCOR-Donor) study, is a national, natural history study of plasma donors recovered from COVID-19. CONCOR-Donor study will address immune response, duration of protective immunity, and clinical factors and host genetics contributing to the variability of immune response. We will also study long-term outcomes from COVID-19 infection. Results from the study will help define therapeutic strategies for COVID-19.
The outbreak caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) led to
the global pandemic. There are currently no proven treatments for coronavirus disease
(COVID-19), however, convalescent plasma has emerged as a potential therapeutic to prevent
clinical deterioration. Convalescent plasma was successfully used for other infections, in
small numbers, but there is limited evidence for the efficacy of administering specific,
neutralizing antibodies by transfusion of convalescent plasma. The unknown role for
convalescent plasma in treating COVID-19 necessitates further study.
As trials are underway to determine efficacy of using convalescent plasma, we will use this
unique opportunity to conduct a national longitudinal cohort study of 1000 persons recovered
from COVID-19 and volunteer to donate convalescent plasma. Our aims are to:1) determine if
the variability of titers of viral neutralizing antibody and ELISA antibody are associated
with clinical and demographic factors; 2) determine duration of protective immunity in
recovered persons over 1 year and if modified by clinical and demographic factors; 3)
determine genetic risk predictors of the antibody response, and 4) create a biorepository
available to researchers from across Canada. Based on the World Health Organization (WHO)
Coordinated Global Research Map, this project addresses the priority of the natural history
of COVID-19 and clinical characterization of antibody response in the convalescent phase and
beyond.
Inclusion Criteria:
- Recovered from COVID-19 infection
- Have a positive PCR or serology or a positive household contact
- Signed informed consent form
- Provide blood sample
- Ability to complete a questionnaire
Exclusion Criteria:
- None
The Hospital for Sick Children
Toronto, Ontario, Canada
Rulan Parekh, MD, Principal Investigator
The Hospital for Sick Children